MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 56 filers reported holding MERSANA THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $433,000 | +56.3% | 107,072 | +102.8% | 0.03% | +130.8% |
| Q1 2019 | $277,000 | +38.5% | 52,800 | +7.3% | 0.01% | -7.1% |
| Q4 2018 | $200,000 | -49.1% | 49,200 | +97.4% | 0.01% | -44.0% |
| Q1 2018 | $393,000 | +84.5% | 24,929 | +91.8% | 0.02% | +127.3% |
| Q4 2017 | $213,000 | -34.1% | 13,000 | -30.4% | 0.01% | -35.3% |
| Q3 2017 | $323,000 | – | 18,688 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |